| Name | Ovoca Bio (CDI) |
|---|---|
| Epic | OVB |
| Isin | IE00B4XVDC01 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 1.65p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £1.46 | Debt ratio | n/a |
| Shares in issue | 88.46 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -173.79 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -6.88 | 52-week high / low | 0.55p / 1.92p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Ovoca Bio (CDI) |
|---|---|
| Address | c/o OBH Partners, 17 Pembroke Street Upper, Dublin 2, Ireland, D02 AT22 |
| Telephone | |
| Website | http://www.ovocabio.com/ |
| Director | Position |
|---|---|
| Mr Kirill Andreyevich Golovanov | CEO |
| Ms Anastasia Levashova | Non-Executive Director |
| Mr Timothy McCutcheon | Non-Executive Director |
| Dr Kristina Zakurdaeva | Independent Non-Executive Director |
| Assets € (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 4.43 | 5.78 | 5.28 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 4.43 | 7.75 | 7.61 |
| Inventory / work in progress | 0.04 | 0.09 | 0.27 |
| Trade and other receivables | 1.23 | 0.33 | 0.04 |
| Cash and equivalents | 3.7 | 6.59 | 10.75 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 9.4 | 14.77 | 19.04 |
| Liabilities € (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 1.56 | 1.34 | 0.45 |
| Long term liabilities | 0.21 | n/a | n/a |
| Other liabilites / pension etc | n/a | n/a | 0.04 |
| Total of all liabilities | 1.77 | 1.34 | 0.49 |
| Net assets € (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 7.63 | 13.43 | 18.55 |
| Equity € (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 11.06 | 11.06 | 11.06 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -9.73 | -2.44 | 3.04 |
| Share premium account | n/a | n/a | n/a |
| Total equity | 7.63 | 13.43 | 18.55 |
| Income € (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -5.58 | -5.33 | -2.53 |
| Pre-tax profit | -5.61 | -5.25 | -2.32 |